The Goldman Sachs Group upgraded shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Get Rating) from a neutral rating to a buy rating in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The firm currently has $68.00 price target on the stock, up from their prior price target of $12.00.
FDMT has been the topic of several other reports. Evercore ISI increased their price target on shares of 4D Molecular Therapeutics from $32.00 to $45.00 in a research report on Monday, November 14th. SVB Leerink increased their price target on shares of 4D Molecular Therapeutics from $10.00 to $11.00 and gave the company a market perform rating in a research report on Thursday, November 10th. Finally, Bank of America increased their price target on shares of 4D Molecular Therapeutics from $15.00 to $25.00 in a research report on Monday, November 14th.
4D Molecular Therapeutics Trading Down 1.8 %
Shares of FDMT opened at $21.99 on Tuesday. The firm’s 50-day moving average is $9.09 and its two-hundred day moving average is $8.77. 4D Molecular Therapeutics has a twelve month low of $5.32 and a twelve month high of $24.38. The firm has a market capitalization of $712.30 million, a P/E ratio of -6.87 and a beta of 1.46.
Hedge Funds Weigh In On 4D Molecular Therapeutics
4D Molecular Therapeutics Company Profile
4D Molecular Therapeutics, Inc, a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease.
- Get a free copy of the StockNews.com research report on 4D Molecular Therapeutics (FDMT)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.